Pulmonary-Allergy Drugs Advisory Committee Meeting

Pulmonary-Allergy Drugs Advisory Committee Meeting Committee Meeting on January 29, 2013 8:00 a.m. to 5:00 p.m. (Day 1 of 2) Agenda: The committee will discuss the new drug application (NDA) 203108, for olodaterol (proposed trade name Striverdi Respimat) metered dose inhaler, sponsored by Boehringer Ingelheim, for the proposed indication of long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.